Related Experiment Video
Updated: Jun 23, 2026
Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
Published on: August 29, 2012
Validated graft-specific biomarkers identify patients at risk for chronic graft-versus-host disease and death
Brent R Logan1, Denggang Fu2, Alan Howard3
1Division of Biostatistics and Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Plasma biomarkers measured 3 months after allogeneic hematopoietic cell transplantation (HCT) can identify patients at high risk for developing chronic graft-versus-host disease (cGVHD). This finding aids in early risk stratification for cGVHD.
Area of Science:
- Hematology
- Immunology
- Transplantation Science
Background:
- Chronic graft-versus-host disease (cGVHD) is a significant complication following allogeneic hematopoietic cell transplantation (HCT).
- Accurate prediction of cGVHD risk is crucial for patient management.
- The role of different graft types (bone marrow vs. peripheral blood) in cGVHD risk necessitates refined biomarker strategies.
Purpose of the Study:
- To identify and validate plasma proteomic biomarkers for predicting cGVHD risk.
- To assess the association of these biomarkers with cGVHD development in patients receiving peripheral blood (PB) or bone marrow (BM) grafts.
- To evaluate the utility of these biomarkers in both human clinical trials and a preclinical mouse model.
Main Methods:
- Plasma proteomics was performed on samples from HCT recipients at day 90 post-transplant.
- Five novel risk markers were identified and combined with eight previously known markers.
- Marker associations with cGVHD risk were analyzed using Cox-proportional-hazards models in two multicenter BMTCTN cohorts, and validated in a mouse model.
Main Results:
- Specific biomarkers (CXCL9, DKK3, CXCL10, MMP3) showed significant correlations and associations with increased cGVHD risk in both PB and BM recipients across cohorts.
- PB recipients with elevated biomarkers demonstrated a significantly higher incidence of cGVHD (22%-32%) compared to those with low biomarkers (8%-12%).
- Elevated circulating biomarkers were detected in a mouse model prior to the onset of cGVHD clinical signs.
Conclusions:
- Plasma biomarker levels at 3 months post-HCT are effective in identifying patients at risk for developing cGVHD.
- These validated biomarkers offer a promising tool for early risk stratification and personalized management of HCT recipients.
- The findings support the use of biomarker scores for predicting cGVHD risk, irrespective of graft source.
More Related Videos
09:00High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
Published on: October 31, 2012
06:06Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
Published on: May 23, 2019
